Compare Flagstar Bank NA (FLG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Tango Therapeutics Inc. — how do they compare? Flagstar Bank NA trades at $11.07 (market cap $4.61B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Flagstar Bank NA is the larger of the two by market cap, and Flagstar Bank NA pays a 0.36% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 23 Days and Tango Therapeutics Inc. for 0 Days on average.
| FLG | TNGX | |
|---|---|---|
Market Cap | $4.61B | $3.74B |
Volume | 4,112,400 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $15.36 | $32.90 |
52-Week Low | $10.72 | $7.50 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $15.13B | $2.76B |
Dividend Yield | 0.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.21, down 0.88% with a bearish technical outlook despite recent earnings beats in Q4 2025 and Q1 2026. The stock shows mixed fundamentals with a low P/B ratio of 0.61x but elevated P/E of 373.67x, while profitability metrics remain weak with net income margin at 2.3%. Recent news highlights strategic partnerships and a $250 million share repurchase program, though Q2 2026 earnings missed expectations.
Wall Street maintains a bullish consensus with 60% buy ratings and a $16.81 price target, representing 50% upside potential. Key risks include volatile earnings performance, high valuation multiples, and negative cash flow trends. The company's turnaround efforts and strong capital position provide potential catalysts, but execution risks remain significant.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
